Columnist Juliet Taylor's late husband, Jeff, always made Christmas special. To honor his memory, she carries on their ...

Data from over 8,000 ALS patients will be fed into Unlearn's Digital Twin Generator, an AI platform that creates duplicates ...

The results of CardinALS showed utreloxastat failed to meet its main and secondary goals, including several disease-related ...

Columnist Dagmar Munn has managed the shift to a rollator, scooter, and other assistive devices that help her live a better ...

The Phase 1 trial ANQUR, now testing two new doses of the ALS therapy QRL-201, is enrolling patients at 12 sites in Canada ...

Growing up in rural areas, having younger parents, and having less education may all be environmental risk factors for ALS, ...

Worrying about symptom progression a year after her diagnosis, columnist Dagmar Munn decided to develop her own resilience ...

Help for family caregivers is urgently needed in the U.S., as the current situation is untenable, writes columnist.

The U.S. Food and Drug Administration (FDA) signaled that it may be willing to consider granting accelerated approval to ...

MN-166 (ibudilast) appears to benefit ALS patients over up to one year of use, an interim Phase 2b/3 trial analysis suggests.

The first ALS patient was dosed in a Phase 1 trial of Quralis' first-in-class therapy QRL-101, which is still enrolling at a ...

MaaT033, an experimental oral therapy for improving gut microbiome health, was shown to be safe and well tolerated in ALS ...